Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on May 16, 2025
Basel Medical Group Ltd Kicks Off US$ 1.0 Billion Bitcoin (BTC) Acquisition Strategy Move
GlobeNewswire
·
May 16, 2025
Singapore, May 16, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL or the “Company”), today announced that it has begun exclusive negotiations for a US$1 billion BTC acquisition that will diversify its treasury reserves to a very large …
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
GlobeNewswire
·
May 16, 2025
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer on Wednesday, May 21st at 2:40 PM ET LA JOLLA, CA, May 16, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an …
SRx Health Solutions Further Diversifies Treasury Strategy with Purchase of Ethereum
GlobeNewswire
·
May 16, 2025
TAMPA, Fla., May 16, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”), a leading global health and wellness company, today announced further diversifying its treasury strategy with the purchase of Ethereum (ETH). …
Psychemedics Named “Most Innovative Drug Testing Company of the Year”
GlobeNewswire
·
May 16, 2025
DALLAS, May 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world’s leading provider of hair drug testing, is proud to announce it has been named “Most Innovative Drug Testing Company of the Year” by Acquisition International Magazine as part of …
Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of…
GlobeNewswire
·
May 16, 2025
PALO ALTO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the …
BON Announces The Launch Of Its Postbiotic Hypoglycemic Patented Ingredient Product Series And Its Cooperation Agreement
GlobeNewswire
·
May 16, 2025
XI’AN, China, May 16, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced an exclusive cooperation agreement with …
Medicines for Poland: Europe Faces a Critical Choice on Medicines and Market Reform
GlobeNewswire
·
May 16, 2025
WARSAW, Poland, May 16, 2025 (GLOBE NEWSWIRE) -- Member States are nearing the end of discussions on EU pharmaceutical reform to ensure affordable medicines and support EU manufacturing in Europe. This will enhance the Union’s strategic resilience and …
Orthopedic Devices Market worth US$68.51 billion by 2030 with 4.8% CAGR | MarketsandMarkets™.
GlobeNewswire
·
May 16, 2025
Delray Beach, FL, May 16, 2025 (GLOBE NEWSWIRE) -- The global orthopedic devices market , valued at US$49.63 billion in 2023, is forecasted to grow at a robust CAGR of 4.8%, reaching US$51.61 billion in 2024 and an impressive US$68.51 billion by 2030. The …
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting
GlobeNewswire
·
May 16, 2025
HOUSTON, May 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic …
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
GlobeNewswire
·
May 16, 2025
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound …
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
GlobeNewswire
·
May 16, 2025
Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and MAINZ, Germany, May 16, 2025 (GLOBE NEWSWIRE) -- Mainz …
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 16, 2025
SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and …
Vivex Biologics, Inc. Executive Chair Nominated for Ernst & Young LLP Entrepreneur of the Year® 2025 Florida Award
GlobeNewswire
·
May 16, 2025
MIAMI, May 16, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced the company’s Executive Chairman, John A. McCallum, has been selected as a finalist in the prestigious Ernst …
Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day
GlobeNewswire
·
May 16, 2025
WOBURN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Thursday, May …
Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
GlobeNewswire
·
May 16, 2025
TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that management will participate in a …
PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025
GlobeNewswire
·
May 16, 2025
TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on ketamine for unmet medical needs, today announced the U.S. Food and Drug …
Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates
GlobeNewswire
·
May 16, 2025
WARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies …
Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting
GlobeNewswire
·
May 16, 2025
Company Urges Stockholders to Vote ‘FOR’ Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE …
QHSLab, Inc. Signals Strategic Debt Restructuring to Strengthen Balance Sheet and Drive Growth
GlobeNewswire
·
May 16, 2025
Company in Advanced Discussions to Restructure Convertible Debt and Unlock Shareholder Value Potential Agreement Expected to Improve Financial Flexibility and Reduce Dilution Pressure WEST PALM BEACH, FL, May 16, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “ …
Paratek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference
GlobeNewswire
·
May 16, 2025
First conference presentations for: Phase 2b study for nontuberculous mycobacterial pulmonary disease (NTM PD) caused by Mycobacterium abscessus complex (MABc) Phase 3 OPTIC-2 study in moderate-to-severe community-acquired bacterial pneumonia (CABP) BOSTON …